Atlas Trials

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Clinical trial NCT05910801 · RECRUITING

Trial details

NCT number
NCT05910801
Sponsor
Academic and Community Cancer Research United
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
Start date
2024-01-04
Primary completion
2029-12-30
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.